fluorouracil and sirolimus

fluorouracil has been researched along with sirolimus in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.56)	18.2507
2000's	11 (17.19)	29.6817
2010's	41 (64.06)	24.3611
2020's	11 (17.19)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Behl, A; Bhat, KA; Chakraborty, S; Chikan, NA; Farooq, S; Goswami, A; Lone, SH; Mondhe, DM; Nayak, D; Rah, B; Rasool, RU	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Mostafa, AS; Selim, KB	1
Liu, Y; Xu, Z; Zhao, SJ	1
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E	1
Herrman, P; Joergensen, J; Quesniaux, VF; Schreier, MH; Schuler, W; Schuurman, HJ; Steiner, C; Wehrli, S	1
Boni, J; Bruntsch, U; Peters, M; Punt, CJ; Thielert, C	1
Bruns, CJ; Doenecke, A; Frank, E; Geissler, EK; Guba, M; Jauch, KW; Koehl, GE; Seeliger, H; Steinbauer, M; Wagner, C	1
Bu, X; Guo, X; Jia, F; Wang, W; Wei, L; Wu, M	1
Bu, X; Guo, X; Jia, F; Le, C; Wei, L; Wu, M; Zhang, B; Zhang, L	1
Collingridge, D	1
August, DA; Shi, Y	1
Akkaya, E; Macaulay, VM; Peak, S; Protheroe, AS; Sullivan, M; Takiguchi, M; Wang, Y; Yuen, JS	1
Candinas, D; Egger, B; Hunt, KK; Laemmle, A; Roh, V; Strehlen, M; Stroka, D; Trochsler, M; Vorburger, SA; Wagner, M	1
Sherman, WH	1
Fung, AS; Tannock, IF; Wu, L	1
Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S	1
Mehta, SP	1
Eriksson, B	1
Hosono, Y; Kawaguchi, Y; Nawa, M; Osada, S; Takahashi, T; Yamaguchi, K; Yoshida, K	1
Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Lee, J; Lee, KH; Oh, DY; Song, SH; Yoon, YK	1
Cannistra, SA; Disis, ML; Verweij, J	1
Albanell, J; Berk, L; Capri, G; Cerny, T; Corradino, I; Cresta, S; Gianni, L; Haluska, F; Hess, D; Locatelli, A; Marsoni, S; Maur, M; Perotti, A; Rivera, VM; Rojo, F; Sessa, C; Viganò, L	1
Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M	1
Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS	1
Alp, E; Konac, E; Menevse, S; Onen, HI; Turktekin, M; Yilmaz, A	1
Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW	1
Breitenbuecher, F; Hähnel, PS; Herbertz, S; Kasper, S; Markova, B; Schuler, M	1
Chang, HM; Kang, YK; Kim, TW; Lee, C; Lee, HJ; Lee, JL; Park, YS; Ryoo, BY; Ryu, MH; Yoon, DH	1
Klümpen, HJ; Kordes, S; Richel, DJ; Stevens, AJ; Weterman, MJ; Wilmink, JW	1
Ekyalongo, RC; Fujiwara, Y; Funakoshi, Y; Imai, Y; Kataoka, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H	1
Kaklamani, V; Raffin, M; Reddy, S	1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C	1
Cai, Z; Chen, Y; He, X; Ke, J; Lan, P; Wang, J; Wang, L; Wu, X; Yuan, R	1
Do, IG; Jung, SH; Kang, WK; Kim, KM; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS	1
Basu, S	1
Akcakanat, A; Brewster, AM; Chen, H; Crawford, D; Do, KA; Dryden, MJ; Flores, P; Giordano, SH; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Litton, JK; Liu, S; Meric-Bernstam, F; Mills, GB; Moore, J; Moulder-Thompson, S; Murray, JL; Palla, SL; Pusztai, L; Sahin, A; Symmans, WF; Tarco, E; Valero, V	1
Arrowood, CC; Bendell, JC; Brady, JC; Broderick, S; Cushman, SM; Dellinger, A; Hsu, SD; Hurwitz, HI; Kozloff, MF; Meadows, J; Meadows, KL; Morse, MA; Murphy, J; Nixon, AB; Pang, H; Rangwala, F; Starodub, AN; Starr, A; Strickler, JH; Tourt-Uhlig, S; Uronis, HE; Wallace, J; Zafar, SY	1
Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG	1
Chang, GR; Chao, TH; Chen, PL; Chen, WY; Mao, FC	1
Chao, Y; Chen, LT; Cheng, AL; Hsu, C; Li, CP; Lin, YL; Lin, ZZ; Shen, YC; Su, WC; Yeh, KH; Yen, CJ	1
Grąt, M; Kornasiewicz, O; Krasnodębski, M; Krawczyk, M; Patkowski, W; Stankiewicz, R	1
Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV	1
Klümpen, HJ; Kordes, S; Richel, DJ; Schellens, JH; Weterman, MJ; Wilmink, JW	1
McKenna, SL; O'Donovan, TR; O'Reilly, S; O'Sullivan, GC; Rajendran, S	1
Angus, PW; Chin, R; Jia, Z; Lim, EJ; Nachbur, U; Silke, J; Torresi, J	1
Bozec, A; Ebran, N; Etienne-Grimaldi, MC; Merlano, M; Milano, G; Monteverde, M; Nigro, CL; Penault-Llorca, F; Radosevic-Robin, N; Sudaka, A; Toussan, N	1
Cheng, J; Colegio, OR; Kim, C	1
Arai, S; Kadowaki, T; Kubota, N; Kurokawa, M; Masamoto, Y; Sato, T; Takamoto, I	1
Chen, SH; Huang, KJ; Kuo, CH; Lee, YR; Lin, CY	1
Liu, T; Yang, JW; Zhang, QH	1
Chen, J; Liu, Y; Qin, C; Shen, Y; Wang, B; Yang, S; Zhao, X	1
Batey, K; Chen, J; Feng, X; Hollinger, MK; Kim, J; Lin, Z; Sun, W; Wu, Z; Young, NS	1
Chen, YQ; Li, ZH; Lin, CY; Yan, PK; Yuan, ZW; Zhu, WT	1
Chang, GR; Chiou, RY; Hou, PH; Kuo, CY; Lin, CF; Lin, TC; Wang, CM; Wu, CF; Wu, CY; Yang, WC	1
Chang, GR; Chen, CH; Kuo, CY; Liao, HJ; Lin, TC; Lin, WL; Tsai, MY; Wang, YC	1
Cao, W; Cui, LL; Guo, JB; Jia, L; Pang, C; Peng, SQ; Zhang, LS; Zhang, TF; Zhao, ZM; Zhu, CH	1
Islam, MK; Lian, HK; Lim, JCW; Sagineedu, SR; Selvarajoo, N; Stanslas, J	1
Bai, JX; Chen, WQ; Ko, JK; Liu, B; Yung, KK; Zhang, SQ; Zhang, Z	1
Chen, S; Gao, X; Liu, Q; Wang, F; Yang, J; Yu, Y; Zhang, Y	1
Hong, Y; Jia, ML; Li, YT; Liu, XM; Liu, ZQ; Yan, PK; Zhu, WT	1
Kaira, K; Komine, C; Nakazawa, N; Ogawa, H; Okada, T; Osone, K; Ozawa, N; Saeki, H; Sakai, M; Sano, A; Shibasaki, Y; Shioi, I; Shirabe, K; Shiraishi, T; Sohda, M; Suga, K; Yokobori, T	1

Reviews

6 review(s) available for fluorouracil and sirolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles	2019
Palliative chemotherapy for pancreatic malignancies. The Surgical clinics of North America, 2010, Volume: 90, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus	2010
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Current opinion in oncology, 2010, Volume: 22, Issue:4 Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome	2010
Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. Seminars in oncology, 2016, Volume: 43, Issue:3 Topics: Carcinoma, Squamous Cell; Cryosurgery; Fluorouracil; Humans; Immunosuppressive Agents; Microsurgery; Organ Transplantation; Photochemotherapy; Radiotherapy; Retinoids; Sentinel Lymph Node Biopsy; Sirolimus; Skin Neoplasms; Transplant Recipients	2016
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment. Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:20 Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB Receptors; Fluorouracil; Humans; Metformin; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Resveratrol; Sirolimus; TOR Serine-Threonine Kinases	2022

Trials

13 trial(s) available for fluorouracil and sirolimus

Article	Year
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Sirolimus	2003
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Cell Cycle Proteins; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Europe; Female; Fluorouracil; Granulation Tissue; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; Skin; Thymidine Phosphorylase; Thymidylate Synthase; TOR Serine-Threonine Kinases; Treatment Outcome	2010
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Stomach Neoplasms; Treatment Outcome	2011
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Young Adult	2012
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Dropouts; Platinum Compounds; Sirolimus; Stomach Neoplasms; Treatment Outcome	2012
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Investigational new drugs, 2013, Volume: 31, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sirolimus; Treatment Outcome	2013
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate	2013
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Investigational new drugs, 2013, Volume: 31, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Sirolimus; Stomach Neoplasms; Young Adult	2013
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms	2014
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Everolimus; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neuropilin-1; Neuropilin-2; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Sirolimus; Vascular Endothelial Growth Factor A	2014
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Monitoring; Early Termination of Clinical Trials; Everolimus; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Protein Kinase Inhibitors; Severity of Illness Index; Sirolimus; TOR Serine-Threonine Kinases	2014
Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology, 2014, Volume: 87, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pilot Projects; Sirolimus; Stomach Neoplasms; Taiwan; Treatment Outcome	2014
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases	2015

Other Studies

45 other study(ies) available for fluorouracil and sirolimus

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death. Journal of medicinal chemistry, 2015, Apr-23, Volume: 58, Issue:8 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Diterpenes; Drug Design; Female; Halogenation; Humans; Membrane Proteins; Mice; Proto-Oncogene Proteins c-bcl-2; Salvia; Sarcoma 180; Signal Transduction; TOR Serine-Threonine Kinases	2015
Synthesis and anticancer activity of new dihydropyrimidinone derivatives. European journal of medicinal chemistry, 2018, Aug-05, Volume: 156 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidinones; TOR Serine-Threonine Kinases	2018
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved? European journal of medicinal chemistry, 2021, Jan-15, Volume: 210 Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2	2021
The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood, 1994, Sep-01, Volume: 84, Issue:5 Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Line; Culture Media, Conditioned; Cytokines; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heart Transplantation; Hematopoiesis; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Interleukin-1; Interleukin-3; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Polyenes; Recombinant Proteins; Reference Values; Sirolimus; Stem Cell Factor; T-Lymphocytes; Transplantation, Homologous	1994
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Aorta, Thoracic; Colonic Neoplasms; Deoxyribose; Disease Models, Animal; Fluorouracil; Immunosuppressive Agents; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Muscle, Smooth, Vascular; Neovascularization, Pathologic; Rats; Rats, Inbred ACI; Sirolimus; Thymidine Phosphorylase	2004
Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC cancer, 2007, Nov-12, Volume: 7 Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Protein Kinases; Signal Transduction; Sirolimus; Telomerase; TOR Serine-Threonine Kinases; Transcription, Genetic	2007
Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer biology & therapy, 2008, Volume: 7, Issue:3 Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Senescence; Fluorouracil; Humans; Liver Neoplasms; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases	2008
San Antonio Breast Cancer Symposium. The Lancet. Oncology, 2008, Volume: 9, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles	2008
A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence. Cancer biology & therapy, 2008, Volume: 7, Issue:3 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cellular Senescence; Fluorouracil; Liver Neoplasms; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases	2008
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Molecular cancer therapeutics, 2009, Volume: 8, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Receptor, IGF Type 1; RNA, Small Interfering; Sirolimus; Transfection; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays	2009
Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:10 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mice; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Sirolimus; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Xenograft Model Antitumor Assays	2009
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer. JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4 Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome	2009
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-01, Volume: 15, Issue:17 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2009
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. World journal of gastroenterology, 2009, Sep-14, Volume: 15, Issue:34 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Sirolimus; Treatment Outcome	2009
Combination therapy of 5-fluorouracil with rapamycin for hormone receptor-negative human breast cancer. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2010
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer letters, 2010, Dec-18, Volume: 299, Issue:1 Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Everolimus; Fluorouracil; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Protein Serine-Threonine Kinases; Sirolimus; Stomach Neoplasms; Thymidylate Synthase; TOR Serine-Threonine Kinases	2010
Phase I studies of drug combinations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Evidence-Based Medicine; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Maximum Tolerated Dose; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome	2010
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anti-cancer drugs, 2011, Volume: 22, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epothilones; Everolimus; Female; Fluorouracil; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Nude; Paclitaxel; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2011
Evaluation of the effects of the flavonoid apigenin on apoptotic pathway gene expression on the colon cancer cell line (HT29). Journal of medicinal food, 2011, Volume: 14, Issue:10 Topics: Anticarcinogenic Agents; Apigenin; Apoptosis; Caspase 3; Caspase 8; Cell Cycle Checkpoints; Cyclin D1; DNA; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; L-Lactate Dehydrogenase; Microscopy, Fluorescence; RNA, Messenger; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2011
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Flow Cytometry; Fluorouracil; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung; Lung Neoplasms; Pemetrexed; Sirolimus; Thymidylate Synthase; Time Factors; TOR Serine-Threonine Kinases	2012
Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. International journal of oncology, 2012, Volume: 41, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gene Amplification; Humans; Paclitaxel; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Trastuzumab	2012
Targeting angiogenesis in metastatic breast cancer. The oncologist, 2012, Volume: 17, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer. Annals of surgical oncology, 2014, Volume: 21, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Prognosis; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2014
A complex interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recovery following 5-fluorouracil treatment. Stem cell research, 2014, Volume: 12, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Fluorouracil; Hematopoietic Stem Cells; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Multiprotein Complexes; Reactive Oxygen Species; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors	2014
The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells. Anticancer research, 2014, Volume: 34, Issue:7 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Fluorouracil; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Ribosomal Protein S6 Kinases; Sirolimus; Vascular Endothelial Growth Factor A	2014
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization. Transplantation proceedings, 2014, Volume: 46, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Calcineurin Inhibitors; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Incidental Findings; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Survival Analysis; Treatment Outcome	2014
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2. European urology, 2015, Volume: 68, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib	2015
Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo. PloS one, 2015, Volume: 10, Issue:8 Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Esophageal Neoplasms; Female; Fluorouracil; Genes, Reporter; Humans; Lithium Chloride; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Organoplatinum Compounds; Oxaliplatin; Sirolimus; Transplantation, Heterologous	2015
Effect of Immunosuppressive Agents on Hepatocyte Apoptosis Post-Liver Transplantation. PloS one, 2015, Volume: 10, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Survival; Cyclosporine; Drug Therapy, Combination; Female; Fluorouracil; Hepatocytes; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Transplantation; Male; Mice; Mice, Inbred C57BL; Middle Aged; Mitomycin; Semustine; Sirolimus; Tacrolimus	2015
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer. The Laryngoscope, 2016, Volume: 126, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cisplatin; ErbB Receptors; Fluorouracil; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2016
Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation. Stem cells (Dayton, Ohio), 2017, Volume: 35, Issue:7 Topics: Adiponectin; Animals; Benzhydryl Compounds; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Epoxy Compounds; Fluorouracil; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Myeloablative Agonists; Poly I-C; Signal Transduction; Sirolimus; Whole-Body Irradiation	2017
Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy. Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:3 Topics: Adenine; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Biphenyl Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Lignans; Macrolides; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2018
Autophagy facilitates anticancer effect of 5-fluorouracil in HCT-116 cells. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Fluorouracil; HCT116 Cells; Humans; Microtubule-Associated Proteins; RNA, Small Interfering; Sirolimus	2018
An acellular tissue matrix-based drug carriers with dual chemo-agents for colon cancer growth suppression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117 Topics: Acellular Dermis; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Carriers; Drug Synergism; Fluorouracil; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Sirolimus	2019
Sirolimus augments hematopoietic stem and progenitor cell regeneration following hematopoietic insults. Stem cells (Dayton, Ohio), 2021, Volume: 39, Issue:2 Topics: Animals; Cell Survival; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Sirolimus; Stem Cells; Whole-Body Irradiation	2021
Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer. International journal of nanomedicine, 2021, Volume: 16 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Inhibitory Concentration 50; Liposomes; Mice; Particle Size; Signal Transduction; Sirolimus; Tissue Distribution; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays	2021
The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice. International journal of molecular sciences, 2021, Apr-27, Volume: 22, Issue:9 Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytokines; ErbB Receptors; Fluorouracil; Humans; Hyaluronan Receptors; Inflammation; Male; Mice, Inbred BALB C; NF-kappa B; Sirolimus; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2021
Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice. Molecules (Basel, Switzerland), 2021, Aug-02, Volume: 26, Issue:15 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Sirolimus; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021
Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022, Volume: 25, Issue:1 Topics: Animals; Cell Line, Tumor; Fluorouracil; Humans; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sirolimus; Stomach Neoplasms	2022
Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 106 Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Chalcones; Drugs, Chinese Herbal; Fluorouracil; Mice; Molecular Docking Simulation; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Sirolimus	2022
Rapamycin Enhanced Sensitivity of HT-29 Cells to 5-Fluororacil by Promoting Autophagy. Bulletin of experimental biology and medicine, 2022, Volume: 173, Issue:4 Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Fluorouracil; HT29 Cells; Humans; Sirolimus	2022
Rapamycin Liposomes Combined with 5-Fluorouracil Inhibits Angiogenesis and Tumor Growth of APC International journal of nanomedicine, 2022, Volume: 17 Topics: Animals; Azoxymethane; Colitis; Colorectal Neoplasms; Dextran Sulfate; Disease Models, Animal; Fluorouracil; Lipopolysaccharides; Liposomes; Mice; Mice, Inbred C57BL; Sirolimus	2022
Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy. International journal of molecular sciences, 2023, Jan-30, Volume: 24, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Oxaliplatin; Sirolimus; TOR Serine-Threonine Kinases	2023